Neratini
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab (NCT05760612) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2023-03-14 |
Track Neratini automatically
Every clearance here is in the API, with alerts when new ones post.